register

News & Trends - MedTech & Diagnostics

The big themes impacting ASX-listed healthcare companies

Health Industry Hub | January 23, 2023 |

MedTech News: The COVID-19 pandemic has significantly impacted many ASX-listed healthcare companies, such as ResMed, Fisher and Paykel Healthcare, Sonic Healthcare and CSL.

Sonic Healthcare and Australian Clinical Labs have benefitted as COVID-19 testing has surged during the last couple of years.

That said, the past three years hasn’t been an unexpected gain for all. Supply chain challenges have impacted companies like ResMed, while lockdowns have prevented CSL from executing its flagship product.

In 2023, the Australian healthcare sector is facing two headwinds. The short-term headwind is the Chinese reopening. The long-term headwind is the impact inflation has on production, according to Citi’s Australian health analysts.

The top three ASX healthcare companies – CSL, ResMed and Fisher and Paykel Healthcare – have pricing power and resilient demand which should offset the negative impact of inflation and/or a potential recession, at least to some degree, according to the analysts.

CSL is focused on plasma collection, recovery in Vifor sales post-COVID, the Argenx CIDP P3 clinical trial data in Q2 2023, and the transition to the Terumo plasma collection devices.

In the case of ResMed, the company continues to benefit from the Philips CPAP medical device recall for sleep aponea. ResMed believes that it will have the capacity to supply the entire market once the availability of semiconductors improves, potentially reducing the likelihood of a quick return to market by Philips.

On the other hand, Ramsay Health Care and Integral Diagnostics continue to face the uncertainty around COVID-19, workforce challenges and the pace of recovery of their businesses. Cochlear could also be hit if the pace and severity of China’s COVID-19 reopening changes dramatically.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


News & Trends - MedTech & Diagnostics

Bowel Cancer Australia advocacy shapes government action on younger age screening

Bowel Cancer Australia advocacy shapes government action on younger age screening

Health Industry Hub | May 16, 2024 |

Bowel Cancer Australia celebrated a significant milestone in its six-year campaign as the Australian Government, in the Federal Budget announcement, […]

More


Medical

Government ignores COVID lessons: Future Made in Australia fund neglects medical products

Government ignores COVID lessons: Future Made in Australia fund neglects medical products

Health Industry Hub | May 16, 2024 |

The $22.7 billion Future Made in Australia investment from the Federal Budget must do more to fully harness the potential […]

More


Medical

Government urged to tackle 14-year decline in R&D investment

Government urged to tackle 14-year decline in R&D investment

Health Industry Hub | May 16, 2024 |

Medical: There is an urgency to counter the fourteen-year downward trend in research and development (R&D) investment, positioning Australia unfavourably […]

More


This content is copyright protected. Please subscribe to gain access.